Page 2 - Operational Progress News Today

Vivoryon Therapeutics N.V. to Report Full Year 2022 Financial Results and Operational Progress on April 19, 2023 Halle (Saale) / Munich, Germany, April 14, 2023 - Vivoryon

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Q3 2022 Financial Results and Operational Progress on November

EQS-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report H1 2022 Financial Results and Operational Progress on September

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Annual Results Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report ...

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Annual Results Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Report Full Year 2021 Financial Results and Operational Progress on April 28, 2022 21.04.2022 / 07:00 The issuer is solely responsible for the content of this announcemen...

Aareal Bank: Erkennt der Markt das Potenzial nicht? - Aktienanalyse (Der Aktionär) | Aktien des Tages | aktiencheck.de

Die Aareal Bank hat gestern ihre endgültigen Zahlen zum abgelaufenen Quartal vorgelegt. 13.08.2021

HAMBURG (dpa-AFX Analyser) - Die Investmentbank Warburg Research hat die Einstufung für Aareal Bank auf "Buy" mit einem Kursziel von 27,50 Euro belassen. Operative Fortschritte ließen die Jahresziele des

  The person responsible for arranging the release of this announcement on behalf of Ultra is Louise Ruppel, General Counsel & Company Secretary.   Disclaimer J.P. Morgan Securities plc, which conducts its UK investment banking business as J.P. Morgan Cazenove ("J.P. Morgan Cazenove"), is authorised in the United Kingdom by the Prudential Regulation Authority (the "PRA") and regulated in the United Kingdom by the PRA and the Financial Conduct Authority. J.P. Morg...